SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib

Thomas O'Hare, Christopher A. Eide, Jeffrey Tyner, Amie S. Corbin, Matthew J. Wong, Sean Buchanan, Kevin Holme, Katayoun A. Jessen, Crystal Tang, Hal A. Lewis, Richard D. Romero, Stephen K. Burley, Michael W. Deininger

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-AblT315I, however, is resistant to all Abl kinase inhibitors in clinical use and is emerging as the most frequent cause of salvage therapy failure. SGX393 is a potent inhibitor of native and T315I-mutant Bcr-Abl kinase that blocks the growth of leukemia cell lines and primary hematopoietic cells expressing Bcr-AblT315I, with minimal toxicity against Bcr-Abl-negative cell lines or normal bone marrow. A screen for Bcr-Abl mutants emerging in the presence of SGX393 revealed concentration-dependent reduction in the number and range of mutations. Combining SGX393 with nilotinib or dasatinib preempted emergence of resistant subclones, including Bcr-Abl T315I. These findings suggest that combination of a T315I inhibitor with the current clinically used inhibitors may be useful for reduction of Bcr-Abl mutants in Philadelphia chromosome-positive leukemia.

Original languageEnglish (US)
Pages (from-to)5507-5512
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume105
Issue number14
DOIs
StatePublished - Apr 8 2008

Fingerprint

Phosphotransferases
Leukemia
bcr-abl Fusion Proteins
Cell Line
Salvage Therapy
Philadelphia Chromosome
Mutation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow
Growth
preempt
In Vitro Techniques
Dasatinib
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Imatinib Mesylate

Keywords

  • Gatekeeper mutation
  • Imatinib resistance
  • Kinase inhibitor

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. / O'Hare, Thomas; Eide, Christopher A.; Tyner, Jeffrey; Corbin, Amie S.; Wong, Matthew J.; Buchanan, Sean; Holme, Kevin; Jessen, Katayoun A.; Tang, Crystal; Lewis, Hal A.; Romero, Richard D.; Burley, Stephen K.; Deininger, Michael W.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 14, 08.04.2008, p. 5507-5512.

Research output: Contribution to journalArticle

O'Hare, T, Eide, CA, Tyner, J, Corbin, AS, Wong, MJ, Buchanan, S, Holme, K, Jessen, KA, Tang, C, Lewis, HA, Romero, RD, Burley, SK & Deininger, MW 2008, 'SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 14, pp. 5507-5512. https://doi.org/10.1073/pnas.0800587105
O'Hare, Thomas ; Eide, Christopher A. ; Tyner, Jeffrey ; Corbin, Amie S. ; Wong, Matthew J. ; Buchanan, Sean ; Holme, Kevin ; Jessen, Katayoun A. ; Tang, Crystal ; Lewis, Hal A. ; Romero, Richard D. ; Burley, Stephen K. ; Deininger, Michael W. / SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 14. pp. 5507-5512.
@article{92a2f26abbce4f609e870c5ef9add394,
title = "SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib",
abstract = "Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-AblT315I, however, is resistant to all Abl kinase inhibitors in clinical use and is emerging as the most frequent cause of salvage therapy failure. SGX393 is a potent inhibitor of native and T315I-mutant Bcr-Abl kinase that blocks the growth of leukemia cell lines and primary hematopoietic cells expressing Bcr-AblT315I, with minimal toxicity against Bcr-Abl-negative cell lines or normal bone marrow. A screen for Bcr-Abl mutants emerging in the presence of SGX393 revealed concentration-dependent reduction in the number and range of mutations. Combining SGX393 with nilotinib or dasatinib preempted emergence of resistant subclones, including Bcr-Abl T315I. These findings suggest that combination of a T315I inhibitor with the current clinically used inhibitors may be useful for reduction of Bcr-Abl mutants in Philadelphia chromosome-positive leukemia.",
keywords = "Gatekeeper mutation, Imatinib resistance, Kinase inhibitor",
author = "Thomas O'Hare and Eide, {Christopher A.} and Jeffrey Tyner and Corbin, {Amie S.} and Wong, {Matthew J.} and Sean Buchanan and Kevin Holme and Jessen, {Katayoun A.} and Crystal Tang and Lewis, {Hal A.} and Romero, {Richard D.} and Burley, {Stephen K.} and Deininger, {Michael W.}",
year = "2008",
month = "4",
day = "8",
doi = "10.1073/pnas.0800587105",
language = "English (US)",
volume = "105",
pages = "5507--5512",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "14",

}

TY - JOUR

T1 - SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib

AU - O'Hare, Thomas

AU - Eide, Christopher A.

AU - Tyner, Jeffrey

AU - Corbin, Amie S.

AU - Wong, Matthew J.

AU - Buchanan, Sean

AU - Holme, Kevin

AU - Jessen, Katayoun A.

AU - Tang, Crystal

AU - Lewis, Hal A.

AU - Romero, Richard D.

AU - Burley, Stephen K.

AU - Deininger, Michael W.

PY - 2008/4/8

Y1 - 2008/4/8

N2 - Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-AblT315I, however, is resistant to all Abl kinase inhibitors in clinical use and is emerging as the most frequent cause of salvage therapy failure. SGX393 is a potent inhibitor of native and T315I-mutant Bcr-Abl kinase that blocks the growth of leukemia cell lines and primary hematopoietic cells expressing Bcr-AblT315I, with minimal toxicity against Bcr-Abl-negative cell lines or normal bone marrow. A screen for Bcr-Abl mutants emerging in the presence of SGX393 revealed concentration-dependent reduction in the number and range of mutations. Combining SGX393 with nilotinib or dasatinib preempted emergence of resistant subclones, including Bcr-Abl T315I. These findings suggest that combination of a T315I inhibitor with the current clinically used inhibitors may be useful for reduction of Bcr-Abl mutants in Philadelphia chromosome-positive leukemia.

AB - Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-AblT315I, however, is resistant to all Abl kinase inhibitors in clinical use and is emerging as the most frequent cause of salvage therapy failure. SGX393 is a potent inhibitor of native and T315I-mutant Bcr-Abl kinase that blocks the growth of leukemia cell lines and primary hematopoietic cells expressing Bcr-AblT315I, with minimal toxicity against Bcr-Abl-negative cell lines or normal bone marrow. A screen for Bcr-Abl mutants emerging in the presence of SGX393 revealed concentration-dependent reduction in the number and range of mutations. Combining SGX393 with nilotinib or dasatinib preempted emergence of resistant subclones, including Bcr-Abl T315I. These findings suggest that combination of a T315I inhibitor with the current clinically used inhibitors may be useful for reduction of Bcr-Abl mutants in Philadelphia chromosome-positive leukemia.

KW - Gatekeeper mutation

KW - Imatinib resistance

KW - Kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=43749086323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749086323&partnerID=8YFLogxK

U2 - 10.1073/pnas.0800587105

DO - 10.1073/pnas.0800587105

M3 - Article

C2 - 18367669

AN - SCOPUS:43749086323

VL - 105

SP - 5507

EP - 5512

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 14

ER -